Viewing Study NCT04265534

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:31 AM
Ignite Modification Date: 2026-02-28 @ 6:29 AM
Study NCT ID: NCT04265534
Status: TERMINATED
Last Update Posted: 2022-09-21
First Post: 2020-02-07
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC
Sponsor: Calithera Biosciences, Inc
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-Small Cell Lung Cancer View
None Non-squamous Non-small-cell Lung Cancer View
None Non-Squamous Non-Small Cell Neoplasm of Lung View
None KEAP1 Gene Mutation View
None NRF2 Gene Mutation View
None NFE2L2 Gene Mutation View
Keywords:

Keywords

Keyword Brief Keyword Text View
None NSCLC View
None KEAP1 View
None NRF2 View
None NFE2l2 View
None LKB1 View
None STK11 View
None Next Generation Sequencing View
None NGS View
None Mutation View
None Pembrolizumab View
None Pemetrexed View
None Carboplatin View
None Randomized View
None Placebo View
None Chemotherapy View
None Targeted Therapy View
None Telaglenastat View
None Glutamine View
None Glutaminase View
None Glutathione View
None Immunotherapy View
None Front-line View
None First-line View
None Non-squamous View
None Keytruda View
None Alimta View
None Guardant360 View